natalizumab news
Your Search Returned 148 tagged news reports
PDL BioPharma Issues Q2 Royalty Guidance
Alexandria :: VA :: USA | 6 days ago
Credibility
The company has issued guidance for the period, estimating that it will take in royalty revenue of around $143 million. That would represent a 13% increase over the Q2 2012 figure of $126 million. PDL BioPharma's optimism derives from the relatively
Tags:
Elan Board Of Directors Unanimously And Without Reservation Rejects Royalty Pharma's Revised Tender Offer
Rome :: Italy | 8 days ago
Credibility
Elan or the Company) today announced that its Board of Directors, after careful review and consideration and with the assistance of its executive management team as well as outside financial and legal advisors, has rejected the revised bid from
Tags:
Royalty Pharma urges U.S. court to let Elan bid proceed
New York City :: NY :: USA | 8 days ago
Credibility
Investment partnership Royalty Pharma on Sunday urged a federal court in New York to allow it to proceed with a potential $8 billion bid for Irish drug company Elan Corp...District Court in Manhattan, Royalty Pharma said that on Friday it provided
Tags:
Royalty Pharma raises bid for Elan to potential $8 billion
Dublin :: Ireland | 11 days ago
Credibility
Royalty Pharma 's $6.4 billion bid for Irish drug firm Elan had been accepted by just 7.5 percent of the target company's shareholders before the U.S...Royalty , seeking to get its hands on Elan's lucrative royalties from multiple sclerosis drug
Tags:
Elan Says Bid Undervalues It by as Much as $8.30 a Share
Dublin :: VA :: USA | 18 days ago
Credibility
board of directors and executive management team, the Ireland-based biotechnology company has determined the recent $12.50-a-share buyout offer from Royalty Pharma undervalues select Elan assets by as much as $4.3 billion, the company announced
Tags:
Elan strikes more deals, agrees second share buyback
Dublin :: Ireland | 29 days ago
Credibility
Kelly Martin, President and CEO of Elan, speaks at the Reuters Health Summit in New York November 17, 2008. Irish drug firm Elan agreed on Monday to buy two private drug firms, spin-off its one experimental drug and buy back more shares to give a
Tags:
Elan board unanimously rejects Royalty Pharma bid
Dublin :: CA :: USA | 1 month ago
Credibility
The board of Irish drugmaker Elan unanimously rejected a formal bid from Royalty Pharma on Monday, saying the U.S...Royalty last week lowered its bid for Elan to $11.25 a share from an earlier $12 per share offer, pricing in the result of a $1
Tags:
Elan Corporation, plc's Board of Directors Unanimously Reject Royalty Pharma's Unsolicited Tender Offer
Alexandria :: VA :: USA | 1 month ago
Credibility
Any holder of 1% or more of any class of relevant securities of Elan or of Royalty Pharma may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2007 (as amended). Forward Looking Statements This document
Tags:
5 Must-Watch Earnings Reports in the Health-Care Sector This Week
New York City :: NY :: USA | 1 month ago
Credibility
Believe it or not, there are times when earnings reports slow down in frequency, but this is certainly not one of those times. In the health-care sector we have 71 companies set to report next week, according to Finviz, so it definitely pays to be
Tags:
Exclusive: Royalty Pharma considers sweetened deal for Elan - sources
New York City :: NY :: USA | 2 months ago
Credibility
Investment firm Royalty Pharma is considering sweetening its $6.6 billion offer for Irish drugmaker Elan to pay Elan shareholders more if the multiple sclerosis drug Tysabri hits certain sales milestones, two people familiar with the matter said on
Tags:
